Name | Type | Posted | Actions |
|---|---|---|---|
A0002 HT9402-26-Q-9101 Amend.pdf | Jan 8, 2026 | ||
A0001 February 2026 PandT Meeting Reporting.xlsx | XLSX | Dec 4, 2025 | |
A0001 HT9402-26-Q-9101 Amend.pdf | Dec 4, 2025 | ||
RFQ HT9402-26-Q-9101 CR.pdf | Nov 18, 2025 | ||
https://health.mil/PandT | LINK | Nov 18, 2025 | |
NDC Price List-Antihemophilic Agents - Non-factor Agents.xlsx | XLSX | Nov 18, 2025 | |
NDC Price List FAQ Class Review.pdf | Nov 18, 2025 | ||
NDC Price List-Oncological Agents - Myelofybrosis.xlsx | XLSX | Nov 18, 2025 |
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
Contact and place of performance
Tracy Banks
San Antonio, TX 78230
USA
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical e...
View morehe RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9101. Pre-quotation teleconference is on November 20, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference.
The Defense Health Agency Aurora, under the TRICARE Management Activity, is soliciting pharmaceutical agents for the Department of Defense (DoD) Pharmacy Uniform Formulary. Pursuant to 10 U.S.C. § 1074g and 32 CFR Section 199.21, the DoD Pharmacy and Therapeutics (P&T) Committee evaluates clinical and cost effectiveness to select agents for the Uniform Formulary and determine cost-sharing classifications. This specific requirement focuses on oncological agents for Myelofibrosis, including Inrebic, Jakafi, Ojjaara, and Vonjo. The government intends to award Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the committee’s findings.
Solicitation HT9402-26-Q-9101 is classified under NAICS code 325412, Pharmaceutical Preparation Manufacturing, and PSC 6505, Drugs and Biologicals. Performance is centered in San Antonio, Texas, with a response deadline of January 16, 2026. The procurement process involves eight total attachments, including the primary Request for Quotation (RFQ), amendment documents, and price lists for various antihemophilic and myelofibrosis agents. A pre-quotation teleconference was scheduled for November 20, 2025, to provide instructions on the submission process. Tracy Banks serves as the point of contact for this requirement.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.